The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Clinical Oncology Next Generation Sequencing (NGS) Market Research Report 2024

Global Clinical Oncology Next Generation Sequencing (NGS) Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1894723

No of Pages : 108

Ask Your Query

Synopsis

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.

The global Clinical Oncology Next Generation Sequencing (NGS) market was valued at US$ 704.7 million in 2023 and is anticipated to reach US$ 1429.7 million by 2030, witnessing a CAGR of 10.6% during the forecast period 2024-2030.

The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.

This report aims to provide a comprehensive presentation of the global market for Clinical Oncology Next Generation Sequencing (NGS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Oncology Next Generation Sequencing (NGS).

Report Scope

The Clinical Oncology Next Generation Sequencing (NGS) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Clinical Oncology Next Generation Sequencing (NGS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Clinical Oncology Next Generation Sequencing (NGS) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Illumina
  • Roche
  • Agilent Technologies
  • Knome
  • Genomatix Software
  • GATC Biotech
  • Oxford Nanopore Technologies
  • Macrogen
  • Life Technologies
  • DNASTAR
  • Exosome Diagnostics
  • Biomatters
  • CLC Bio
  • BGI
  • Qiagen
  • Perkin Elmer
  • Pacific Bioscience
  • Partek
  • GnuBIO
  • Foundation Medicine
  • Paradigm
  • Caris Life Sciences
  • Myriad Genetics

Segment by Type

  • NGS Pre-Sequencing
  • Sequencing
  • NGS Data Analysis
  • Primary, Secondary & Tertiary Data Analysis

Segment by Application

  • Academic & Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Clinical Oncology Next Generation Sequencing (NGS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 NGS Pre-Sequencing
1.2.3 Sequencing
1.2.4 NGS Data Analysis
1.2.5 Primary, Secondary & Tertiary Data Analysis
1.3 Market by Application
1.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Academic & Clinical Research
1.3.3 Hospitals & Clinics
1.3.4 Pharma & Biotech Entities
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2019-2030)
2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Region
2.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Region (2019-2024)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Region (2025-2030)
2.3 Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
2.3.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Trends
2.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
2.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
2.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2019-2024)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2019-2024)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2023
3.5 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.6 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.7 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2019-2024)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2025-2030)
5 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Application (2019-2024)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2019-2030)
6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2019-2024)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2019-2030)
7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2019-2024)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (2019-2030)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2019-2024)
8.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2019-2030)
9.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2019-2024)
9.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size (2019-2030)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2019-2024)
10.4 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.1.5 Illumina Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.3.5 Agilent Technologies Recent Development
11.4 Knome
11.4.1 Knome Company Detail
11.4.2 Knome Business Overview
11.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.4.5 Knome Recent Development
11.5 Genomatix Software
11.5.1 Genomatix Software Company Detail
11.5.2 Genomatix Software Business Overview
11.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.5.5 Genomatix Software Recent Development
11.6 GATC Biotech
11.6.1 GATC Biotech Company Detail
11.6.2 GATC Biotech Business Overview
11.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.6.5 GATC Biotech Recent Development
11.7 Oxford Nanopore Technologies
11.7.1 Oxford Nanopore Technologies Company Detail
11.7.2 Oxford Nanopore Technologies Business Overview
11.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.7.5 Oxford Nanopore Technologies Recent Development
11.8 Macrogen
11.8.1 Macrogen Company Detail
11.8.2 Macrogen Business Overview
11.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.8.5 Macrogen Recent Development
11.9 Life Technologies
11.9.1 Life Technologies Company Detail
11.9.2 Life Technologies Business Overview
11.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.9.5 Life Technologies Recent Development
11.10 DNASTAR
11.10.1 DNASTAR Company Detail
11.10.2 DNASTAR Business Overview
11.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.10.5 DNASTAR Recent Development
11.11 Exosome Diagnostics
11.11.1 Exosome Diagnostics Company Detail
11.11.2 Exosome Diagnostics Business Overview
11.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.11.5 Exosome Diagnostics Recent Development
11.12 Biomatters
11.12.1 Biomatters Company Detail
11.12.2 Biomatters Business Overview
11.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.12.5 Biomatters Recent Development
11.13 CLC Bio
11.13.1 CLC Bio Company Detail
11.13.2 CLC Bio Business Overview
11.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.13.5 CLC Bio Recent Development
11.14 BGI
11.14.1 BGI Company Detail
11.14.2 BGI Business Overview
11.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.14.5 BGI Recent Development
11.15 Qiagen
11.15.1 Qiagen Company Detail
11.15.2 Qiagen Business Overview
11.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.15.5 Qiagen Recent Development
11.16 Perkin Elmer
11.16.1 Perkin Elmer Company Detail
11.16.2 Perkin Elmer Business Overview
11.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.16.5 Perkin Elmer Recent Development
11.17 Pacific Bioscience
11.17.1 Pacific Bioscience Company Detail
11.17.2 Pacific Bioscience Business Overview
11.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.17.5 Pacific Bioscience Recent Development
11.18 Partek
11.18.1 Partek Company Detail
11.18.2 Partek Business Overview
11.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.18.5 Partek Recent Development
11.19 GnuBIO
11.19.1 GnuBIO Company Detail
11.19.2 GnuBIO Business Overview
11.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.19.5 GnuBIO Recent Development
11.20 Foundation Medicine
11.20.1 Foundation Medicine Company Detail
11.20.2 Foundation Medicine Business Overview
11.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.20.5 Foundation Medicine Recent Development
11.21 Paradigm
11.21.1 Paradigm Company Detail
11.21.2 Paradigm Business Overview
11.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.21.5 Paradigm Recent Development
11.22 Caris Life Sciences
11.22.1 Caris Life Sciences Company Detail
11.22.2 Caris Life Sciences Business Overview
11.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.22.5 Caris Life Sciences Recent Development
11.23 Myriad Genetics
11.23.1 Myriad Genetics Company Detail
11.23.2 Myriad Genetics Business Overview
11.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2019-2024)
11.23.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock